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Abstract 
Background: Scant data exist on incidence rates, correlates, and prognosis of 
electrocardiographic P-wave abnormalities in the general population. 
Methods: We recorded ECG and measured conventional cardiovascular risk factors in 5667 
community-dwelling Finns who were followed up for incident atrial fibrillation (AF). We 
obtained repeat ECGs from 3089 individuals 11 years later. 
Results: The incidence rates of prolonged P-wave duration, abnormal P terminal force (PTF), 
left P-wave axis deviation, and right P-wave axis deviation were 16.0%, 7.4%, 3.4%, and 
2.2%, respectively. Older age and higher BMI were associated with incident prolonged P-
wave duration and abnormal PTF (30.01). Higher blood pressure was associated with 
incident prolonged P-wave duration and right P-wave axis deviation (P0.01). During follow-
up, only prolonged P-wave duration predicted AF (multivariable-adjusted hazard ratio, 1.38; 
P=0.001). 
Conclusions: Modifiable risk factors associate with P-wave abnormalities that are common 
and may represent intermediate steps of atrial cardiomyopathy on a pathway leading to AF. 
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Introduction 
 
Alterations in electrocardiographic P-wave morphology, e.g. prolonged P-wave duration, P 
terminal force (PTF), and abnormal P-wave axis, may be indicative of atrial remodeling and of 
an underlying pathological process [1,2]. More importantly, alterations in P-wave morphology 
also seem to have clinical significance, as they have been shown to predict atrial fibrillation 
(AF) and ischemic stroke [3-6]. 
 
Aging, male sex, obesity, and hypertension have been shown to cross-sectionally correlate 
with prolonged P-wave duration and PTF [7-9]. However, cross-sectional data are not ideal 
for establishing causation, and longitudinal data on the incidence and correlates of abnormal 
P-wave indices are scant. A better understanding of this domain could therefore elucidate the 
clinical factors mainly responsible for atrial electroanatomic remodeling, and help identify 
individuals at increased risk for incident AF and stroke. We therefore conducted a longitudinal 
study in a large, representative, nationwide population sample to determine 1) the prevalence 
and incidence rates of P-wave abnormalities in the general population; 2) the clinical factors 
associated with incident P-wave abnormalities; and 3) the distinct P-wave abnormalities 
associated with incident AF.  
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Material and methods 
 
Study sample 
This study is based on the Health 2000 Survey, a nationwide epidemiological survey carried 
out in Finland between 2000 and 2001. The survey sample consisted of 8028 individuals 
representative of the Finnish adult population aged 30 years who were randomly drawn from 
the population register. The participation rate was 79% (n=6354). A detailed description of the 
survey protocol and methods has been published previously [10]. 
 
The correlates of prevalent P-wave abnormalities and association between P-wave 
abnormalities and incident AF were assessed in a sample where participants with one or 
more of the following exclusion factors were excluded: missing ECG (n=55), previous 
diagnosis of AF/atrial flutter or AF/atrial flutter on the study ECG (n=208), Wolf-Parkinson-
White ECG pattern (n=2), paced rhythm (n=12), unmeasurable P waves (n=110), or missing 
baseline covariates (n=440). After exclusions, 5667 participants were included in these 
analyses. 
 
A follow-up study of the Health 2000 Survey cohort, the Health 2011 Survey, was carried out 
in 2011–2012 using similar methods as the baseline survey. 3242 of the 5667 individuals 
included in the baseline analyses took part in the re-examination. After excluding participants 
with incident AF/atrial flutter (n=140), Wolf-Parkinson-White ECG pattern (n=0), paced rhythm 
(n=12), or unmeasurable P waves at re-examination (n=89), 3089 (55%) participants had no 
missing baseline or follow-up data. After further excluding participants with prevalent P-wave 
abnormalities at baseline, 2831, 2710, 2948, and 2972 participants were included in the 
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longitudinal analyses for correlates of incident prolonged P-wave duration, abnormal PTF, left 
P-wave axis deviation, and right P-wave axis deviation, respectively. We also assessed the 
reversal of P-wave abnormalities between baseline and follow-up in 258, 379, 141 and 117 
participants with prolonged P-wave duration, abnormal PTF, left P-wave axis deviation, and 
right P-wave axis deviation at baseline, respectively. 
 
Study flow 
Information on health, illnesses, medications and functional capacity were collected by 
centrally trained interviewers at the participants’ homes during the baseline survey and at a 
local facility during the follow-up survey [10]. A physical examination was performed for each 
participant at a local health center by centrally trained doctors and nurses. Height, weight and 
body circumference were measured and fasting blood samples for serum lipids and glucose 
were taken from each participant. The study protocols were carried out according to the 
Declaration of Helsinki and were approved by the ethical committee of the hospital district of 
Helsinki and Uusimaa. All participants gave written informed consent. 
 
ECG recordings and definitions of P-wave abnormalities 
During the health examination, standard 12-lead ECGs were recorded in the resting supine 
position using standard procedures and a MAC 5000 recorder in 2000–2001 (Marquette 
Hellige, Freiburg, Germany, and Milwaukee, WI, USA) and a MAC5500 recorder (GE 
Healthcare, Freiburg, Germany) in 2011–2012. The electronic recordings were analyzed with 
the Magellan software (GE Healthcare, Milwaukee, WI, USA), and the measurements were 
manually checked, and if necessary, corrected by centrally trained nurses supervised by an 
experienced clinical physiologist. 
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Prolonged P-wave duration was determined as the maximum P-wave duration in any lead 
>120ms [5]. Abnormal PTF was determined as the product of the duration and the amplitude 
of the terminal portion of P wave -4 mVms in lead V1 [11]. Left P-wave axis deviation was 
defined as P-wave axis <0° and right P-wave axis deviation as P-wave axis >75° [12]. 
 
Covariates 
Blood pressure was measured with a standard mercury manometer from the right arm after a 
10-min rest. The means of two measurements performed at a two-minute interval were used 
to determine blood pressure. Diabetes mellitus was defined as fasting serum glucose level of 
7.0 mmol/L or greater, or a history of the use of oral hypoglycemic agents or insulin therapy. 
Current smoking was defined as daily use of tobacco products. Serum non-high-density 
lipoprotein (non-HDL) cholesterol concentration was calculated as total cholesterol minus 
HDL-cholesterol. Chronic obstructive pulmonary disease (COPD) was defined as having been 
diagnosed with COPD by a physician and receiving medication for COPD; or having a 
spirometry result indicative of COPD according to the Global Initiative for Chronic Obstructive 
Lung Disease criteria [13]. Use of chronotropic medication (beta-blockers, digitalis, calcium-
channel blockers, and antiarrhythmic agents) was determined based on the participant’s self-
reported use of medication prescriptions in the health interview. 
 
Prevalent cardiac disease and follow-up for AF 
Information on prevalent and incident cardiovascular disease was obtained from the National 
Hospital Discharge register. This register contains information on all periods of inpatient 
(since 1967) and outpatient (since 1998) care in all Finnish secondary- and tertiary-care 
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hospitals. Diagnoses are registered in this register by the treating physicians with codes 
defined in the 10th revision of the International Classification of Diseases (ICD-10). In 
addition, data on causes of death, drug purchases, and entitlements to special 
reimbursements due to chronic diseases was gathered from the Causes of Death and Drug 
Reimbursement registers. All aforementioned registers are nationwide with a full coverage for 
all participants who continued to live in Finland. Prevalent coronary heart disease was 
determined as previous hospitalization with ICD-10 codes I20-I22 and/or percutaneous 
coronary intervention or coronary artery bypass surgery. Prevalent heart failure was 
determined as previous hospitalization with any of the ICD-10 codes I50, I110, I130, I132; or if 
a participant had purchased furosemide on at least three occasions or had obtained the right 
for reimbursement for medication costs for heart failure. The coronary heart disease and heart 
failure diagnoses of the previously mentioned registers have been previously validated 
[14,15]. Incident AF was defined as the ICD-10 code I48 in the National Hospital Discharge or 
Causes of Death registers during follow-up or AF in the Health 2011 Survey follow-up ECG. 
Follow-up for incident AF ended on December 31, 2013. 
 
Statistical analyses 
We assessed the differences in baseline characteristics between individuals with and without 
P-wave abnormalities using the chi-squared, the Wilcoxon rank sum, and the Kruskal-Wallis 
tests. We examined the cross-sectional and longitudinal associations between baseline 
characteristics and P-wave abnormalities using logistic regression. We included baseline age, 
sex, systolic blood pressure, BMI, non-HDL-cholesterol, smoking, diabetes, use of 
chronotropic medication, COPD, prevalent heart failure, and prevalent coronary heart disease 
in the models as independent variables. We included these variables in the models due to 
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their significance as cardiovascular risk factors, or due to their potential impact on the P-wave 
abnormalities. We used Cox proportional hazards regression model to evaluate the 
association of P-wave abnormalities with incident AF. We adjusted these models for baseline 
age, sex, smoking, systolic blood pressure, non-HDL-cholesterol, BMI, diabetes, coronary 
heart disease, heart failure, and heart rate. We confirmed the proportional hazards 
assumption with the Kolmogorov-type supremum test. We performed a sensitivity analysis 
with abnormal PTF defined as -6 mVms as in a previous publication [16]. We used Kaplan–
Meier curves to evaluate the incidence of AF in participants with and without prolonged P-
wave duration. All statistical analyses were performed using SAS 9.4 (SAS Institute Inc., 
Cary, NC, USA). Two-tailed P<0.05 was considered statistically significant.  
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Results 
 
Study sample 
The baseline characteristics of the whole study sample are shown in Table 1. The prevalence 
rates of prolonged P-wave duration, abnormal PTF, left P-wave axis deviation, and right P-
wave axis deviation were 9.9%, 15.2%, 5.1%, and 4.6% at baseline, respectively. Participants 
with P-wave abnormalities were older and had a greater prevalence of heart failure, coronary 
heart disease, and chronotropic medication use than those with normal P-waves. 
 
Cross-sectional determinants of P-wave abnormalities 
In multivariable-adjusted logistic regression analyses, participants with prolonged P-wave 
duration, abnormal PTF, and right P-wave axis deviation were more likely to be older (Table 
2). Participants with prolonged P-wave duration were more likely to be male, have higher BMI, 
and use chronotropic medication. Participants with abnormal PTF were more likely to have 
higher systolic blood pressure and smoke, but less likely to have COPD. Participants with 
right P-wave axis deviation were more likely to be male, smoke, and have COPD, heart 
failure, lower BMI, and lower non-HDL-cholesterol. 
 
Longitudinal changes and determinants of change in P-wave abnormalities 
Changes in P-wave abnormality statuses during follow-up are shown in Figure 1. The 
incidence rates of prolonged P-wave duration, abnormal PTF, left P-wave axis deviation, and 
right P-wave axis deviation after an 11-year follow-up were 16.0%, 7.4%, 3.4% and 2.2%, 
respectively. The reversal of prolonged P-wave duration, abnormal PTF, left P-wave axis 
deviation, and right P-wave axis deviation occurred respectively in 50.4%, 68.9%, 66.0%, and 
9 
 
61.5% of the participants with prevalent P-wave abnormalities at baseline. The association of 
baseline characteristics with incident P-wave abnormalities is shown in Table 3. Older age, 
male sex, higher systolic blood pressure, and higher BMI were associated with incident 
prolonged P-wave duration. Older age, higher BMI, and prevalent coronary heart disease 
were related to incident abnormal PTF. Higher systolic blood pressure, lower BMI, smoking, 
prevalent heart failure, and prevalent COPD were associated with incident right P-wave axis 
deviation. 
 
To assess the possibility of selection bias in the longitudinal analyses; we compared the 
baseline characteristics of participants who were re-examined to those who did not attend re-
examination. Participants who were not re-examined were older and more likely to be men 
(P<0.001 for both, data not shown). In addition, these individuals had higher blood pressure, 
higher BMI, higher non-HDL-cholesterol, higher heart rate, and a greater prevalence rates of 
diabetes, coronary heart disease, COPD, heart failure and chronotropic medication use than 
those who attended re-examination (P<0.001 for all, data not shown). In addition, participants 
who were not re-examined had significantly greater baseline P-wave duration (104.7 ms vs. 
103.9 ms; P=0.03) and PTF (-2.3 mVms vs. -2.0 mVms, P<0.001) than those who were re-
examined. 
 
Association of P-wave abnormalities with incident AF 
During a mean follow-up of 11.9±2.9 years, 423 participants had 1 episode of AF. The 
unadjusted and multivariable-adjusted hazard ratios (HR) and 95% confidence intervals (CI) 
for incident AF are presented in Table 4. In the unadjusted Cox models, the rates of incident 
AF were higher among participants with baseline prolonged P-wave duration (HR, 2.52; 95% 
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CI, 1.99-3.20), abnormal PTF (HR, 1.72; 95% CI, 1.37-2.17), left P-wave axis deviation (HR, 
1.50; 95% CI, 1.03-2.18), and right P-wave axis deviation (HR, 1.81; 95% CI, 1.25-2.63). 
However, in the multivariable-adjusted models, only prolonged P-wave duration was a 
significant predictor of AF: (HR, 1.38; 95% CI, 1.08-1.76). This association became even 
stronger (HR, 1.75; 95% CI, 1.27-2.41) when individuals on chronotropic medication (n=809) 
were excluded. The cumulative risk of AF in individuals with and without prolonged P-wave 
duration is illustrated in Figure 2. Abnormal PTF and P-wave axis were not associated with 
incident AF in the multivariable-adjusted models in the overall sample and in participants not 
on chronotropic medication (P0.16 for all). We also performed a sensitivity analysis with PTF 
defined as -6 mVms (data not shown) and found no association between this marker and 
incident AF (P=0.23). However, when participants on chronotropic medication were excluded, 
the association between abnormal PTF (defined as -6mVms) and AF became significant 
(HR, 1.79; 95% CI, 1.14-2.82; P=0.01). 
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Discussion 
 
Our results demonstrate that the prevalence and incidence rates of P-wave abnormalities are 
relatively high in the general population. In addition, our results demonstrate high reversal 
rates of P-wave abnormalities during follow-up. To the best of our knowledge, this study is the 
first to describe the long-term changes in electrocardiographic atrial measures. Older age, 
systolic blood pressure and BMI, in particular, were associated with prevalent and incident P-
wave abnormalities. Furthermore, we confirmed in an unselected, nationwide, population 
sample previous findings suggestive of an association between prolonged P-wave duration 
and AF. In addition, abnormal PTF defined as -6 mVms, but not as -4 mVms, predicted AF 
in participants not on chronotropic medication. Abnormal P-wave axis was not related to 
incident AF in our sample. 
 
Prolonged P-wave duration 
We observed that prolonged P-wave duration is a common phenomenon in the general 
population. At baseline, 9.9% of individuals in our sample had prolonged P-wave duration, 
and it emerged in 16.0% of participants during follow-up. In agreement with previous studies 
[7-9], older age, male sex and higher BMI were cross-sectionally associated with prolonged 
P-wave duration in our study. The same variables, plus systolic blood pressure, were also 
independently related to incident prolonged P-wave duration. In view of these findings, 
especially BMI and hypertension seem to contribute causally to the electroanatomic 
remodeling of the atria. 
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In our study, prolonged P wave duration was predictive of AF. In addition, this association 
became even stronger when participants on chronotropic medication were excluded using a 
similar approach as in a previous publication [5]. These results are in accordance with 
findings previous studies performed with patient [17] and population [4,5] cohorts that have 
shown an association between prolonged P-wave duration and incident AF. 
 
Abnormal PTF 
The prevalence of abnormal PTF in our study was 15.2%. This is slightly higher than in 
previous studies with manual or automatized ECG measurements, in which the observed 
prevalence rates were 7.5%, and 10.1% respectively [6,16]. Previous cross-sectional works 
have identified advancing age, BMI and hypertension as correlates of abnormal PTF [7,8]. In 
addition to an association with older age and higher systolic blood pressure, we found that 
abnormal PTF was positively related to smoking and inversely related to COPD cross-
sectionally. This inverse relationship with COPD is an expected finding and underlines that 
lung disorders need to be accounted for in analyses concerning PTF. However, in our 
longitudinal analyses, older age, higher BMI and prevalent coronary heart disease, were 
associated with incident abnormal PTF. The observed associations between higher BMI, and 
both abnormal PTF and prolonged P-wave duration, strongly suggest a link between obesity 
and development of atrial cardiomyopathy. 
 
In contrast to previous large-scale epidemiological studies [4,5], abnormal PTF was not 
associated with incident AF in our study. However, this association became significant in 
participants not on chronotropic medication when abnormal PTF was defined as -6 mVms 
instead of -4mVms as in a previous publication [16]. In addition to supporting a limited 
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association between incident AF and abnormal PTF, our results also raise the need to study 
the optimal definition of abnormal PTF. 
 
P-wave axis deviation 
In accord with our results, previous studies have observed that individuals with abnormal P-
wave axis are elderly with tendency for low BMI and high prevalence of COPD [3,12]. Our 
study further clarifies that these associations are largely driven by right P-wave axis deviation 
instead of left P-wave axis deviation. In our study, higher systolic blood pressure, lower BMI 
and prevalent COPD were associated with the incident right P-wave axis deviation. The 
strong association between COPD and right P-wave axis deviation is not surprising as lung 
disorders affect the orientation of the heart in the thoracic cavity and, thus, cause a rightward 
shift to the P-wave axis [18]. On the other hand, central obesity may affect the diaphragm 
causing a leftward shift to the P-wave axis, which explains the association between lower BMI 
and rightward P-wave axis [19]. 
 
In contrast to a previous study [3], abnormal P-wave axis was not associated with incident AF 
in our study which may be due to differences in study samples. In the study by Rangel et al., 
the participants were older with a higher prevalence of abnormal P-wave axis and a higher 
incidence of AF than our study. Furthermore, participants with abnormal P-wave axis in our 
study had significantly higher prevalence rates of heart failure and coronary heart disease 
than those in the study by Rangel et al. which could explain the observed lack of association 
between abnormal P-wave axis and incident AF. In a previous study, we observed no 
association between abnormal P-wave axis and incident coronary heart disease supporting a 
limited prognostic significance of abnormal P-wave axis in the general population [20]. 
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Reversal of P-wave abnormalities 
It is important to note that over half of the baseline P-wave abnormalities had reversed to 
normal at re-examination, which suggests considerable lability in P-wave morphology. 
However, this may also in large part reflect regression to the mean. Furthermore, our results 
may overestimate the reversal rates of P-wave abnormalities to some extent because 
individuals with the most severe forms of P-wave abnormalities were less likely to attend the 
re-examination. Unfortunately, the low number of individuals with prevalent P-wave 
abnormalities that reversed to normal during follow-up prevented us from performing formal 
analyses on the possible correlates of this phenomenon. In any case, this finding warrants 
further research in even larger population cohorts. 
 
Context to current literature 
P-wave abnormalities have been suggested as reflections of electroanatomic remodeling of 
the atria, and thereby a potential substrate for AF [2,3,5]. Consequently, our results 
underscore the potential usefulness of P-wave abnormalities as intermediate biomarkers of 
atrial cardiomyopathy on a pathway leading to AF. We observed that several risk factors that 
associate with AF and ischemic stroke, such as obesity and hypertension, also seem to be 
associated with the incidence of prolonged P-wave duration and abnormal PTF. Of note, both 
obesity and hypertension are modifiable risk factors and treating them reduces the risk of 
incident AF [21,22]. Our study suggests that changes in P-wave abnormalities could possibly 
be used for the evaluation of treatment success and estimating risk of incident AF. In addition, 
given the usefulness of P-wave abnormalities in ischemic stroke prediction in individuals 
without evidence of AF, future studies comparing anticoagulation versus antiplatelet therapy 
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in individuals with ECG markers of atrial cardiomyopathy might be warranted [23]. In recent 
years, partial and advanced interatrial blocks have also gained wide interest in this setting 
and proved to have considerable clinical relevance [24-27]. Advanced interatrial block in 
particular, defined as prolonged P-wave duration with biphasic waveform in inferior leads, has 
been shown to strongly predict AF and stroke in the general population [28,29]. Unfortunately, 
we were underpowered to study the correlates and prognosis of advanced interatrial block in 
our study sample because of the low number of individuals affected with advanced interatrial 
block. 
 
Limitations 
Our study has several limitations. First, although our baseline study sample was relatively 
large, approximately half of the participants were not re-examined due to death and other 
causes, which lowers the representativeness of the follow-up sample. However, this limitation 
affects only the results on incidence and reversal of P-wave abnormalities, and not results 
concerning incident AF that were based on nationwide register data. Second, P-wave 
measurements were performed on only two visits which may not be enough to describe the 
full natural history of P-wave abnormalities. However, our study is the first to describe the 
long-term changes in P-wave abnormalities. Third, we are not yet able to assess how the 
long-term changes of P-wave abnormalities affect the risk of incident AF. Fourth, the data on 
prevalent and incident AF were primarily based on register information from secondary and 
tertiary care. As a consequence, it is likely that some AF paroxysms were only diagnosed in 
primary care or were left undiagnosed and were thus not accounted for in our analyses. Fifth, 
our results may not be generalizable to other ethnicities. Finally, echocardiographic data on 
atrial measures were not available for this study. However, electrocardiographic and 
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echocardiographic variables measure different aspects of the heart’s physiology and therefore 
complement one another [17].  
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Conclusions 
 
Our results contribute to the existing literature on P-wave abnormalities and clarify the role of 
P-wave abnormalities as intermediate risk factors for AF. We conclude that P-wave 
abnormalities are frequent findings in the general population. Our results also highlight high 
reversal rates of P-wave abnormalities during follow-up – a finding that requires confirmation 
in other populations. Modifiable risk factors that have been previously shown to associate with 
incident AF and stroke, such as obesity and hypertension, also seem to be associated with 
the incidence of prolonged P-wave duration and abnormal PTF. P-wave abnormalities, and 
especially prolonged P-wave duration, may represent intermediate steps of atrial 
cardiomyopathy on a pathway leading to AF and can be used to estimate future risk of AF. 
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Tables 
 
Table 1. Baseline characteristics by P-wave abnormality status. 
 
Values are means (standard deviations) for continuous data and numbers (percentages) for categorical data. BMI, body mass 
index; BP, blood pressure; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; HDL, high-density 
lipoprotein cholesterol. P value indicates the significance in difference (Wilcoxon rank sum test or Kruskal-Wallis test for 
continuous and chi-square test for categorical data) between the groups.  
   P-wave duration  P terminal force  P-wave axis 
Characteristic Study sample   120 ms >120 ms 
P 
value   > -4 mVms  -4mVms 
P 
value   0° to 75° < 0° > 75° 
P 
value 
n 5667  5107 560   4807 860   5114 291 262  
Age, years 51.5 (14.1)  50.9 (14.0) 57.3 (14.2) <0.001  50.2 (13.7) 59.0 (14.2) <0.001  51.2 (13.9) 52.9 (15.0) 56.8 (16.3) <0.001 
Men 2577 (45.5)  2260 (44.3) 317 (56.6) <0.001  2177 (45.3) 400 (46.5) 0.50  2294 (44.9) 144 (49.5) 139 (53.1) 0.01 
Systolic BP, mmHg 134.1 (20.8)  133.4 (20.6) 140.1 (21.6) <0.001  132.4 (20.2) 143.5 (21.8) <0.001  134.0 (20.7) 134.7 (21.0) 135.2 (21.9) 0.69 
Diastolic BP, mmHg 81.9 (11.0)  81.7 (10.9) 83.6 (11.1) <0.001  81.5 (10.8) 83.9 (11.5) <0.001  82.0 (11.0) 82.0 (10.3) 78.8 (10.0) <0.001 
BMI, kg/m² 26.9 (4.6)  26.7 (4.6) 28.1 (4.7) <0.001  26.8 (4.6) 27.6 (4.6) <0.001  27.0 (4.6) 27.2 (4.2) 24.6 (4.6) <0.001 
Non-HDL, mmol/l 4.6 (1.1)  4.6 (1.2) 4.7 (1.1) 0.007  4.6 (1.2) 4.8 (1.1) <0.001  4.6 (1.1) 4.6 (1.1) 4.4 (1.2) 0.006 
Current smoking 1249 (22.0)  1152 (22.6) 97 (17.3) 0.005  1074 (22.3) 175 (20.4) 0.19  1115 (21.8) 59 (20.3) 75 (28.6) 0.03 
Diabetes 319 (5.6)  271 (5.3) 48 (8.6) 0.002  233 (4.9) 86 (10.0) <0.001  278 (5.4) 22 (7.6) 19 (7.3) 0.16 
Heart failure 203 (3.6)  157 (3.1) 46 (8.2) <0.001  140 (2.9) 63 (7.3) <0.001  172 (3.4) 9 (3.1) 22 (8.4) <0.001 
CHD 149 (2.6)  107 (2.1) 42 (7.5) <0.001  102 (2.1) 47 (5.5) <0.001  121 (2.4) 11 (3.8) 17 (6.5) <0.001 
COPD 313 (5.5)  273 (5.4) 40 (7.1) 0.08  250 (5.2) 63 (7.3) 0.01  254 (5.0) 17 (5.8) 42 (16.0) <0.001 
Heart rate/min 63.1 (10.6)  63.3 (10.5) 61.4 (11.3) <0.001  62.6 (10.4) 65.6 (11.5) <0.001  63.1 (10.6) 61.2 (9.1) 64.6 (11.1) <0.001 
Chronotropic medication 809 (14.3)   656 (12.9) 153 (27.3) <0.001   618 (12.9) 191 (22.2) <0.001   707 (13.8) 57 (19.6) 45 (17.2) 0.009 
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Table 2. Association between clinical variables and prevalent P-wave abnormalities. 
 Odds ratios (95% confidence intervals) 
Characteristic Prolonged P-wave duration   Abnormal P terminal force   P-wave axis < 0°   P-wave axis > 75° 
Age, 10 years 1.26 (1.16-1.36)***  1.41 (1.32-1.50)***  1.09 (0.98-1.21)  1.36 (1.22-1.51)*** 
Men 1.79 (1.48-2.15)***  1.09 (0.93-1.27)  1.24 (0.97-1.59)  1.54 (1.18-2.01)** 
Systolic BP, 10 mmHg 1.02 (0.98-1.08)  1.14 (1.09-1.18)***  0.97 (0.90-1.04)  0.99 (0.93-1.07) 
BMI, 5 kg/m² 1.23 (1.11-1.36)***  1.02 (0.94-1.12)  1.02 (0.89-1.18)  0.45 (0.37-0.54)*** 
Non-HDL, mmol/l 0.98 (0.91-1.07)  1.01 (0.95-1.09)  0.97 (0.87-1.08)  0.86 (0.76-0.97)* 
Current smoking 0.87 (0.69-1.11)  1.27 (1.05-1.54)*  0.94 (0.70-1.28)  1.41 (1.05-1.91)* 
Diabetes  0.90 (0.64-1.27)  1.27 (0.96-1.68)  1.26 (0.78-2.02)  1.18 (0.70-2.00) 
CHD 1.52 (1.00-2.32)  1.43 (0.96-2.14)  1.14 (0.57-2.29)  1.33 (0.70-2.52) 
Heart failure 1.28 (0.87-1.89)  1.22 (0.86-1.72)  0.62 (0.30-1.28)  1.97 (1.13-3.43)* 
COPD 0.81 (0.56-1.17)  0.71 (0.52-0.97)*  1.03 (0.61-1.74)  1.81 (1.21-2.71)** 
Chronotropic medication 1.58 (1.24-2.01)***   0.98 (0.79-1.22)   1.44 (1.02-2.03)*   0.94 (0.62-1.40) 
 
*P < 0.05; **P < 0.01; ***P < 0.001; BMI, body mass index; BP, blood pressure; CHD, coronary heart disease; COPD, chronic 
obstructive pulmonary disease; HDL, high-density lipoprotein cholesterol. Each of the four models included all the listed 
characteristics as covariates. Odds ratios for P-wave axis were computed using 0° to 75° as reference. 
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Table 3. Association between clinical variables and incident P-wave abnormalities. 
 Odds ratios (95% confidence intervals) 
 Prolonged P-wave duration  Abnormal P terminal force  P-wave axis < 0°  P-wave axis > 75° 
Characteristic (n = 453 of 2831 analyzed)   (n = 200 of 2710 analyzed)   (n = 99 of 2948 analyzed)   (n = 66 of 2972 analyzed) 
Age, 10 years 1.29 (1.16-1.44)***  1.53 (1.31-1.79)***  1.01 (0.82-1.25)  1.12 (0.86-1.45) 
Men 2.14 (1.72-2.66)***  1.08 (0.80-1.46)  1.19 (0.79-1.79)  1.06 (0.64-1.77) 
Systolic BP, 10 mmHg 1.11 (1.04-1.18)**  1.01 (0.93-1.11)  1.01 (0.89-1.14)  1.23 (1.08-1.40)** 
BMI, 5 kg/m² 1.53 (1.35-1.74)***  1.26 (1.06-1.50)**  1.01 (0.79-1.29)  0.49 (0.34-0.71)*** 
Non-HDL, mmol/l 0.98 (0.88-1.08)  1.07 (0.93-1.22)  1.10 (0.91-1.32)  0.88 (0.69-1.13) 
Current smoking 0.83 (0.62-1.11)  1.14 (0.76-1.71)  0.73 (0.42-1.28)  1.94 (1.12-3.36)* 
Diabetes  0.86 (0.49-1.51)  1.21 (0.55-2.62)  0.95 (0.32-2.88)  0.19 (0.01-2.97) 
CHD 0.93 (0.40-2.17)  3.21 (1.35-7.59)**  1.28 (0.31-5.25)  0.56 (0.07-4.48) 
Heart failure 1.03 (0.45-2.36)  0.59 (0.17-2.03)  2.63 (0.81-8.55)  5.51 (1.44-21.09)* 
COPD 1.32 (0.71-2.45)  0.42 (0.13-1.39)  0.95 (0.26-3.47)  4.34 (1.83-10.33)*** 
Chronotropic medication 1.13 (0.78-1.63)   1.18 (0.73-1.91)   1.50 (0.79-2.86)   1.21 (0.53-2.79) 
 
*P < 0.05; **P < 0.01; ***P < 0.001; BP, blood pressure; BMI, body mass index; CHD, coronary heart disease; COPD, chronic 
obstructive pulmonary disease; HDL, high-density lipoprotein cholesterol. Each of the four models included all the listed 
characteristics as covariates.  
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Table 4. Association between P-wave abnormalities and incident atrial fibrillation. 
    Hazard ratio 
   
AF events per 1000 person-
years 
     
P-wave 
characteristic n 
AF events 
(%) Crude (95% CI) P value Adjusted
† (95% CI) P value 
P-wave duration        
    120 ms 5107 337 (6.6) 5.5 1.00 (reference)  1.00 (reference)  
   > 120 ms 560 86 (15.4) 13.7 2.52 (1.99-3.20) <0.001 1.38 (1.08-1.76) 0.001 
P terminal force        
   > -4mVms 4807 331 (6.9) 5.7 1.00 (reference)  1.00 (reference)  
    -4 mVms 860 92 (10.7) 9.7 1.72 (1.37-2.17) <0.001 0.95 (0.75-1.21) 0.68 
P-wave axis        
   0° - 75° 5114 363 (7.1) 5.9 1.00 (reference)  1.00 (reference)  
   < 0° 291 30 (10.3) 8.8 1.50 (1.03-2.18) 0.03 1.16 (0.80-1.69) 0.43 
 > 75° 262 30 (11.5) 10.6 1.81 (1.25-2.63) 0.002 1.31 (0.90-1.92) 0.16 
 
AF, atrial fibrillation; CI, confidence interval. †Adjusted for baseline age, sex, systolic blood pressure, BMI, non-HDL-cholesterol, 
current smoking, diabetes, prevalent heart failure, prevalent coronary heart disease and heart rate. 
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Figures 
 
Figure 1. Longitudinal changes in P-wave abnormalities during 11-year follow-up. Panel A: Incidence of P-wave 
abnormalities in individuals without P-wave abnormalities at baseline. Panel B: Reversal of P-wave abnormalities in 
individuals with P-wave abnormalities at baseline. P-dur, P-wave duration; PTF, P terminal force. 
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Figure 2. Kaplan-Meier curves for incident atrial fibrillation in participants with normal and prolonged (>120ms) P-wave 
duration. AF, atrial fibrillation. 
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